Key result
ACE inhibitors reduce progression to ESRD in non-diabetic renal disease.
Authors
Loading...
ACE inhibitors merit first-line use in non-diabetic renal disease to delay ESRD; confirms renoprotection beyond BP reduction.
Meta-Analysis
Jeffrey S. Berns (2002) conducted a meta-analysis in Non-diabetic renal disease. Angiotensin-converting enzyme (ACE) inhibitors vs. Antihypertensive regimens not containing ACE inhibitors was evaluated on End-stage renal disease (ESRD). Angiotensin-converting enzyme inhibitors reduce the progression of non-diabetic renal disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: